Duloxetine Capsule, Delayed Release
Product Images NDC 68788-8608

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-8608). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (69d6387b 794f 415d 8013 23cca0a6984f 01)

Chemical structure of Duloxetine hydrochloride showing a naphthalene ring attached to a chiral center connected to a thiophene ring and a methylamino group with a hydrochloride salt.*

FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 02)

Kaplan-Meier plot showing the proportion of patients with relapse over time (days) comparing Duloxetine versus placebo treatments. The y-axis represents the proportion of patients with relapse, and the x-axis shows time from randomization to relapse in days. Duloxetine and placebo are distinguished by different line styles.*

FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 03)

A Kaplan-Meier survival curve comparing the proportion of patients with relapse over time between two treatments: placebo and duloxetine. The x-axis shows time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse, ranging from 0 to 1. The graph includes a legend identifying the placebo group with a dashed line and the duloxetine group with a solid line.*

FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares results for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. The graph illustrates how patient improvement varies across different doses of Duloxetine and placebo.*

FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 05)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups, showing a higher percentage of improvement for both Duloxetine dosages compared to placebo across varying pain improvement levels.*

FDA Label Image

Fig 5 (69d6387b 794f 415d 8013 23cca0a6984f 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups, illustrating their relative effectiveness in pain improvement.*

FDA Label Image

Fig 6 (69d6387b 794f 415d 8013 23cca0a6984f 07)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two separate lines), and placebo. Percentage improved decreases as percent improvement in pain increases.*

FDA Label Image

Fig 7 (69d6387b 794f 415d 8013 23cca0a6984f 08)

A line graph titled 'Percentage of Pediatric Patients Aged 13 to 17 Years old with Juvenile Fibromyalgia Syndrome Achieving Various Levels of Pain Relief at week 12 (Study FM-4)'. It compares the percentage of patients improved on the vertical axis to the percent improvement in pain from baseline on the horizontal axis, showing two lines for Duloxetine 60 mg once daily and placebo. Duloxetine consistently shows a higher percentage of patients experiencing pain relief across all levels of pain improvement compared to placebo.*

FDA Label Image

Figure 8 (69d6387b 794f 415d 8013 23cca0a6984f 09)

A graph illustrating the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares duloxetine 60/120 mg once daily to placebo, showing higher patient improvement percentages across varying levels of pain improvement for duloxetine.*

FDA Label Image

Figure 9 (69d6387b 794f 415d 8013 23cca0a6984f 10)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines compare placebo (marked with x) and Duloxetine 60 mg once daily (marked with diamonds), showing higher patient improvement percentages with Duloxetine across various percent improvement intervals.*

FDA Label Image

Figure 10 (69d6387b 794f 415d 8013 23cca0a6984f 11)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for placebo and duloxetine 60/120 mg once daily. Two curves show the distribution of patient improvement, with placebo and duloxetine groups displaying a downward trend as percent improvement in pain increases.*

FDA Label Image

Duloxetine Delayed-release Cap Usp 30mg (69d6387b 794f 415d 8013 23cca0a6984f 13)

Label for Duloxetine Delayed-Release Capsules USP 30 mg, a generic for Cymbalta. The label states each capsule contains 33.7 mg of Duloxetine Hydrochloride equivalent to 30 mg Duloxetine. Manufactured by Lupin Limited. The label includes cautions, storage instructions, and has a barcode and a QR code. The labeler is Preferred Pharmaceuticals, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.